

Agenda • Saturday, November 18, 2006

- 7:15 am Registration and Continental Breakfast
- 7:55 **Introduction and Welcome**
Harry Drabkin, MD, Fernando Kim, MD, L. Michael Glode, MD
- Moderator** Frank V. deGruy, III, MD, Head of Family Medicine
- 8:00-8:30 Prostate cancer screening – what’s new. Who should be screened: when and how.
L. Michael Glode, MD
- 8:30-9:00 Targeted therapy for localized prostate cancer
E. David Crawford, MD
- 9:00-9:10 Laparoscopic Radical Prostatectomy
Fernando Kim, MD
- 9:10-9:40 Where are we in the management of low and high risk prostate cancer in 2006?
David Raben, MD
- 9:40-10:10 Follow up and management of morbidities after primary treatment of prostate cancer.
Thomas W. Flaig, MD
- 10:10-10:30 **Question and Answer Session**
- 10:30-11:00 Vaccines and other adjuvant therapies: do they work and what about quality of life.
L. Michael Glode, MD
- 11:00-11:30 What causes kidney cancer – Molecular Pathogenesis 101 (made easy).
Harry Drabkin, MD
- 11:30-12:00 pm New and effective treatments for metastatic RCC
Harry Drabkin, MD
- 12:00-12:30 Minimally invasive surgery for RCC – patients are out the next day – incredible ?
Fernando Kim, MD
- 12:30-12:50 **“Working Lunch”**
- 12:50-1:20 Bladder cancer - what a primary doctor should know.
Shandra Wilson, MD
- 1:20-1:40 The most important clinical trials in GU Oncology – why you should know.
Thomas W. Flaig, MD
- 1:40-1:55 Support for patients with GU cancer
Kathryn Breaker, RN
- 1:55-2:10 Panel Discussion
Faculty
- 2:10 pm **Adjourn**
- 2:10 – 2:45 Optional tour of the new Fitzsimons campus and GU Oncology.

More Information

Accreditation

The University of Colorado School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Colorado School of Medicine designates this educational activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Registration Fee

\$75.00 - Physicians
\$40.00 - Allied Health Professionals

The registration fee includes continental breakfast, refreshments, syllabus and CME certificate or certificate of attendance for non physicians.

Cancellation

The full conference fee is refundable, less a \$20.00 processing fee, if your cancellation is received in writing, prior to Wednesday, November 3, 2006. The processing fee is nonrefundable regardless of the reason for cancellation. No refunds will be granted after the deadline or for non attendance. The conference committee reserves the right to cancel this conference in the event of an unforeseen circumstance, or if the minimum acceptable registration is not attained. In the event of a cancellation the Office of CME is obligated to refund the registration fee only.

Location

University of Colorado at Denver and Health Sciences Center
Fitzsimons Campus
Research Tower North Auditorium

Directions

The Conference is in the North Research Tower on the Fitzsimons campus.

Parking and directions will change due to construction, please check the website at www.uchsc.edu for current information

To reach the Fitzsimons campus from I-25 and I-70 — take I-70 east to Peoria, South on Peoria to Montview, or East on Colfax to Quentin depending on construction.

Accommodations

For overnight accommodations the Doubletree Hotel is recommended. It is located at 3203 Quebec Street, Denver, Colorado. Please call 303-321-3333 for reservations.

For More Information

Office of Continuing Medical Education at 800-882-9153 or 303-372-9063 or email cme.meetings@uchsc.edu. Conference Manager – Susan Morrison. To view the program, print a registration form, or register online, please visit: www.uchsc.edu/cme

Registration

GU Oncology Conference • November 18, 2006 • Aurora, Colorado

Last Name _____ First Name _____ MI _____
(Print name as you would like it to appear on your CME certificate)

Degree: MD DO PhD PharmD PA Other

Address _____

Zip _____ City _____ State _____

Office Phone _____ Fax Number _____ Email _____

Registration Fee:

Physicians \$75
Allied Health Professionals \$40

(Only registrations with credit card payments are accepted by fax, phone and online. If you fax your registration, please do not send an original by mail.)

Enclosed is my check made payable to the University of Colorado School of Medicine or:


Visa MasterCard Credit card number _____ Exp. date _____

Cardholder Signature _____

 Please indicate if you have any special assistance needs _____

Detach and mail to:
GUO-UCDHSC-CME
4200 East Ninth Avenue, C-295
Denver, CO 80262

You may register online at www.uchsc.edu/cme. Click on the “Register Now” button. Payment by Visa or MasterCard is required to register online. When you register online, you will receive immediate confirmation of your conference registration. (This site uses industry-standard Secure Sockets Layer (SSL) encryption technology to protect your credit card information.)



ONCOLOGY CONFERENCE

SATURDAY, NOVEMBER 18, 2006

University of Colorado at Denver
and Health Sciences Center
Fitzsimons Campus
Research Tower North Auditorium

Presented by
Departments of Medical Oncology
and the Division of Urology
University of Colorado at Denver
and Health Sciences Center

Sponsored by
University of Colorado
School of Medicine
Office of Continuing Medical Education



This program is a part of the Colorado Statewide
Extended Campus. State funds were not used to
develop or administer this program.


ONCOLOGY CONFERENCE

SATURDAY, NOVEMBER 18, 2006

University of Colorado at Denver
and Health Sciences Center
University of Colorado School of Medicine
Continuing Medical Education
4200 E. 9th Avenue, C295
Denver, Colorado 80262

Non-Profit Org.
U.S. Postage
PAID
Denver, Colorado
Permit 2378

General Information



Conference Overview

This Conference is for the educational purpose of updating the Primary Care Physician in regards to diagnosis, treatment and follow up of the prostate, kidney, and bladder cancer patient (*Genitourinary - the urinary system including kidneys, bladder, penis, etc.*). The conference will include how to manage morbidities associated with primary therapy (incontinence, urgency, impotence) and will give the physician an understanding of upcoming new treatments. The conference will cover the new exciting discoveries of what causes Renal Cell Carcinoma (RCC), the new effective therapies for metastatic disease, and the use of laparoscopic surgery to minimize morbidity and hasten the discharge and recovery of patients. The target audience for this conference is Primary Care Physicians and Allied Health Professionals in Primary Care.

Learning Objectives:

At the conclusion of this program, the participants should be able to:

A. Prostate cancer

1. Recognize the pros, cons, and options for prostate cancer screening, and how to better counsel patients.
2. Identify which patients require screening early.
3. Recognize new treatment or follow-up options for low-grade, low-threat prostate cancer.
4. Evaluate minimally invasive techniques for treating prostate cancer including: new radiotherapy techniques, high-frequency ultrasound, laparoscopic/robotic surgery, focal cryotherapy.
5. Identify the follow-up of patients after definitive treatment and what are the treatment options when a recurrence is identified.
6. How to manage morbidities associated with primary therapy (incontinence, urgency, impotence).
7. Describe the potential future role of vaccines and their mechanisms of action.
8. Develop an awareness of ongoing adjuvant trials for treating high-risk disease.
9. Evaluate the impact of chemotherapy on the life of hormone refractory patients.

University of Colorado at Denver and Health Sciences Center

Faculty

Course Directors

Harry A. Drabkin, MD, Medical Oncology
L. Michael Glode, MD, Medical Oncology
Fernando Kim, MD, Urology

Kathryn Breaker, RN, Clinical Trials Manager
Luciano Costa, MD, Medical Oncology
E. David Crawford, MD Urology
Frank V. deGruy, III, MD, Head of Family Medicine
Thomas W. Flaig, MD, Medical Oncology
David Raben, MD, Radiation Therapy
Shandra Wilson, MD, Urology



B. Renal Cell Carcinoma (RCC)

1. Develop an overall understanding of the pathogenesis of kidney cancer and the significance of different histologic types, particularly as this relates to treatment.
2. Identify when RCC may be hereditary and what's available for diagnosis and screening.
3. Recognize when minimal (laparoscopic) surgery is the best approach?
4. What are the new biologic treatments for RCC. How do they work and what are the common side effects that can be handled by a PCP?
7. Why do the new treatments eventually fail?
8. What about a clinical trial - what are the risks and benefits?
9. Are there support groups for patients with RCC?

C. Bladder Cancer

1. Recognize the difference in treatment and prognosis for superficial and invasive bladder cancer.
2. Appraise the terminology for bladder cancer (transurethral resection, continent cutaneous diversion etc.).
3. Recognize the basics of diversion options for bladder cancer in patients with muscle-invasive disease.
4. Translate the data regarding radiation for bladder cancer.
5. Develop contacts for referral for patients requiring treatment for bladder cancer.